Alkermes plc. business relationships
Companies named in Alkermes plc.’s 10-K filed 2026-02-25, and public companies whose annual reports name Alkermes plc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 6.1 / 10
- AI naming
- 100 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in Alkermes plc.’s annual report 13
“Lundbeck A/S plc; VRAYLAR (cariprazine), which is marketed and sold by Abbvie Inc.; COBENFY (xanomeline and trospium chloride), which is marketed and sold by Bristol-Myers Squibb Company; UZEDY; other oral compounds currently on the market; and generic versions of branded oral products.” SEC filing
“Following FDA approval of VUMERITY in 2019, Biogen is responsible for all development and commercialization activities for VUMERITY and all other products covered by the patents that we licensed to Biogen.” SEC filing
“Under our license agreements with Janssen, Biogen and other licensees and sublicensees, the licensees and sublicensees are typically responsible for the commercialization of any products developed under their respective agreements if and when regulatory approval is obtained.” SEC filing
“Under the license and collaboration agreement, Biogen appointed us as the toll manufacturer of clinical and commercial supplies of VUMERITY, subject to Biogen's right to manufacture or have manufactured commercial supplies as a back-up manufacturer.” SEC filing
“In addition, VUMERITY, a licensed product for which we receive royalties, was previously manufactured by us and is now manufactured exclusively by Biogen and its designees, and we no longer have any control over its manufacturing.” SEC filing
“Under the terms of a settlement and license agreement entered into in July 2019 with Amneal Pharmaceuticals LLC ("Amneal"), we granted Amneal a non-exclusive license under certain patents covering VIVITROL, including the remaining patent covering VIVITROL in the U.S., to market and sell a generic fo...” SEC filing
“...into collaborative arrangements with pharmaceutical companies including, among others, Janssen Pharmaceuticals, Inc. ("Janssen, Inc."), Janssen Pharmaceutica International, a division of Cilag International AG ("Janssen International"), and Janssen Pharmaceutica N.V. (together with Janssen, Inc., J...” SEC filing
“...ich we granted Amneal certain rights to distribute and sell in the U.S. an authorized generic version of VIVITROL (the "Amneal AG Product") for a one-year term beginning on the date of a Third Party ANDA Product Launch (as defined in the AG Agreement); provided, however , that if a Third Party ANDA...” SEC filing
“In addition, we rely heavily on the three largest pharmaceutical wholesalers in the U.S. market-Cardinal Health Inc., Cencora, and McKesson Corp-in the distribution of ARISTADA and ARISTADA INITIO, LYBALVI and VIVITROL.” SEC filing
“In addition, we rely heavily on the three largest pharmaceutical wholesalers in the U.S. market-Cardinal Health Inc., Cencora, and McKesson Corp-in the distribution of ARISTADA and ARISTADA INITIO, LYBALVI and VIVITROL.” SEC filing
“Settlement and License Agreement by and between Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Limited and Avadel CNS Pharmaceuticals, LLC and Flamel Ireland Limited.” SEC filing
“Lundbeck A/S plc; VRAYLAR (cariprazine), which is marketed and sold by Abbvie Inc.; COBENFY (xanomeline and trospium chloride), which is marketed and sold by Bristol-Myers Squibb Company; UZEDY; other oral compounds currently on the market; and generic versions of branded oral products.” SEC filing
“In addition, we rely heavily on the three largest pharmaceutical wholesalers in the U.S. market-Cardinal Health Inc., Cencora, and McKesson Corp-in the distribution of ARISTADA and ARISTADA INITIO, LYBALVI and VIVITROL.” SEC filing
Companies whose annual reports name Alkermes plc. 3
“Rondo Partners LLC purchases inventory from Alkermes Plc for resale.” SEC filing
“..., Merck Sharp & Dohme Corp., and Novartis Pharma AG, to emerging growth pharmaceutical and biotechnology companies, including Alkermes Inc., Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and Idorsia Pharmaceuticals Ltd. We also deliver solutions to companies in the consumer products industries.” SEC filing
“...with narcolepsy have available to them a variety of medications, such as generic and/or branded forms of Xyrem and Xywav, which are marketed by Jazz; Wakix, which is marketed by Harmony Biosciences LLC; Lumryz, which is marketed by Alkermes plc; Provigil and Nuvigil, which are manufactured by Teva.” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.